SK49499A3 - 2-methoxyphenylpiperazine derivatives - Google Patents
2-methoxyphenylpiperazine derivatives Download PDFInfo
- Publication number
- SK49499A3 SK49499A3 SK494-99A SK49499A SK49499A3 SK 49499 A3 SK49499 A3 SK 49499A3 SK 49499 A SK49499 A SK 49499A SK 49499 A3 SK49499 A3 SK 49499A3
- Authority
- SK
- Slovakia
- Prior art keywords
- imidazo
- formula
- indolizinyl
- compound
- pyridinyl
- Prior art date
Links
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical class COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- -1 2-indolizinyl Chemical group 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 8
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 8
- 150000002391 heterocyclic compounds Chemical class 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 208000019022 Mood disease Diseases 0.000 claims abstract description 5
- 208000022821 personality disease Diseases 0.000 claims abstract description 5
- 208000027626 Neurocognitive disease Diseases 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 17
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 15
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- LCCQUAVRRQQTLG-UHFFFAOYSA-N 2,3-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CN=C2SCCN21 LCCQUAVRRQQTLG-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229910001516 alkali metal iodide Inorganic materials 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract description 8
- 230000036506 anxiety Effects 0.000 abstract description 4
- 239000007858 starting material Substances 0.000 description 19
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 16
- 229960004170 clozapine Drugs 0.000 description 15
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 15
- KNWASYXLJCYACD-UHFFFAOYSA-N 2-[4-(2-chloroethoxy)phenyl]indolizine Chemical compound C1=CC(OCCCl)=CC=C1C1=CN2C=CC=CC2=C1 KNWASYXLJCYACD-UHFFFAOYSA-N 0.000 description 14
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 13
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 12
- 229960004046 apomorphine Drugs 0.000 description 12
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000003693 atypical antipsychotic agent Substances 0.000 description 9
- 229940127236 atypical antipsychotics Drugs 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000009194 climbing Effects 0.000 description 7
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 6
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229960003878 haloperidol Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- BVLWMAVGQBIIRG-UHFFFAOYSA-N 2-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy]phenyl]indolizine Chemical compound COC1=CC=CC=C1N1CCN(CCOC=2C=CC(=CC=2)C2=CN3C=CC=CC3=C2)CC1 BVLWMAVGQBIIRG-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 3
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000002197 limbic effect Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- GSEZHQBHGMMKBC-UHFFFAOYSA-N 2-[4-(3-chloropropoxy)phenyl]imidazo[1,2-a]pyrimidine Chemical compound C1=CC(OCCCCl)=CC=C1C1=CN(C=CC=N2)C2=N1 GSEZHQBHGMMKBC-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960003750 ethyl chloride Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- ZGWQDMTYAQEMHA-UHFFFAOYSA-N hydron;1-(2-methoxyphenyl)piperazine;dichloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCNCC1 ZGWQDMTYAQEMHA-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BGRJTUBHPOOWDU-LLVKDONJSA-N (R)-(+)-sulpiride Chemical compound CCN1CCC[C@@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-LLVKDONJSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- YQRSBXAKVWRPQC-UHFFFAOYSA-N 2-[4-(2-chloroethoxy)phenyl]imidazo[1,2-a]pyridine Chemical compound C1=CC(OCCCl)=CC=C1C1=CN(C=CC=C2)C2=N1 YQRSBXAKVWRPQC-UHFFFAOYSA-N 0.000 description 1
- BYVYSAZPJWCRCG-UHFFFAOYSA-N 2-[4-(2-chloroethoxy)phenyl]imidazo[1,2-a]pyrimidine Chemical compound C1=CC(OCCCl)=CC=C1C1=CN(C=CC=N2)C2=N1 BYVYSAZPJWCRCG-UHFFFAOYSA-N 0.000 description 1
- IIFRBHNWECOXEQ-UHFFFAOYSA-N 2-[4-(3-chloropropoxy)phenyl]imidazo[1,2-a]pyridine Chemical compound C1=CC(OCCCCl)=CC=C1C1=CN(C=CC=C2)C2=N1 IIFRBHNWECOXEQ-UHFFFAOYSA-N 0.000 description 1
- BWYDNJWRFBNTCU-UHFFFAOYSA-N 2-[4-(4-chlorobutoxy)phenyl]imidazo[1,2-a]pyridine Chemical compound C1=CC(OCCCCCl)=CC=C1C1=CN(C=CC=C2)C2=N1 BWYDNJWRFBNTCU-UHFFFAOYSA-N 0.000 description 1
- GYQJIQVIAUFGAG-UHFFFAOYSA-N 2-[4-(4-chlorobutoxy)phenyl]imidazo[1,2-a]pyrimidine Chemical compound C1=CC(OCCCCCl)=CC=C1C1=CN(C=CC=N2)C2=N1 GYQJIQVIAUFGAG-UHFFFAOYSA-N 0.000 description 1
- OKPIDZKGHIBTGG-UHFFFAOYSA-N 2-[4-(4-chlorobutoxy)phenyl]indolizine Chemical compound C1=CC(OCCCCCl)=CC=C1C1=CN2C=CC=CC2=C1 OKPIDZKGHIBTGG-UHFFFAOYSA-N 0.000 description 1
- SKWZVQACVDRNJK-UHFFFAOYSA-N 2-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy]phenyl]imidazo[1,2-a]pyridine Chemical compound COC1=CC=CC=C1N1CCN(CCOC=2C=CC(=CC=2)C=2N=C3C=CC=CN3C=2)CC1 SKWZVQACVDRNJK-UHFFFAOYSA-N 0.000 description 1
- PVRCKYIRJXKBTL-UHFFFAOYSA-N 2-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy]phenyl]imidazo[1,2-a]pyrimidine Chemical compound COC1=CC=CC=C1N1CCN(CCOC=2C=CC(=CC=2)C=2N=C3N=CC=CN3C=2)CC1 PVRCKYIRJXKBTL-UHFFFAOYSA-N 0.000 description 1
- ACYTXKHLNJBSQH-UHFFFAOYSA-N 2-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy]phenyl]indolizine;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCOC=2C=CC(=CC=2)C2=CN3C=CC=CC3=C2)CC1 ACYTXKHLNJBSQH-UHFFFAOYSA-N 0.000 description 1
- LNFJZMYMJHIQPZ-UHFFFAOYSA-N 2-[4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]imidazo[1,2-a]pyridine Chemical compound COC1=CC=CC=C1N1CCN(CCCOC=2C=CC(=CC=2)C=2N=C3C=CC=CN3C=2)CC1 LNFJZMYMJHIQPZ-UHFFFAOYSA-N 0.000 description 1
- CQKICKAARHHVQQ-UHFFFAOYSA-N 2-[4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]imidazo[1,2-a]pyrimidine Chemical compound COC1=CC=CC=C1N1CCN(CCCOC=2C=CC(=CC=2)C=2N=C3N=CC=CN3C=2)CC1 CQKICKAARHHVQQ-UHFFFAOYSA-N 0.000 description 1
- QYJOQGRYWDIBBL-UHFFFAOYSA-N 2-[4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]indolizine Chemical compound COC1=CC=CC=C1N1CCN(CCCOC=2C=CC(=CC=2)C2=CN3C=CC=CC3=C2)CC1 QYJOQGRYWDIBBL-UHFFFAOYSA-N 0.000 description 1
- RSPDSQGVKCJJFC-UHFFFAOYSA-N 2-[4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]indolizine dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCCOC=2C=CC(=CC=2)C2=CN3C=CC=CC3=C2)CC1 RSPDSQGVKCJJFC-UHFFFAOYSA-N 0.000 description 1
- LUUKEDLOUSMCGZ-UHFFFAOYSA-N 2-[4-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]phenyl]imidazo[1,2-a]pyridine Chemical compound COC1=CC=CC=C1N1CCN(CCCCOC=2C=CC(=CC=2)C=2N=C3C=CC=CN3C=2)CC1 LUUKEDLOUSMCGZ-UHFFFAOYSA-N 0.000 description 1
- HAOCMJCSPLORJR-UHFFFAOYSA-N 2-[4-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]phenyl]imidazo[1,2-a]pyrimidine Chemical compound COC1=CC=CC=C1N1CCN(CCCCOC=2C=CC(=CC=2)C=2N=C3N=CC=CN3C=2)CC1 HAOCMJCSPLORJR-UHFFFAOYSA-N 0.000 description 1
- FBMYMDJCGVVKFC-UHFFFAOYSA-N 2-[4-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]phenyl]indolizine Chemical compound COC1=CC=CC=C1N1CCN(CCCCOC=2C=CC(=CC=2)C2=CN3C=CC=CC3=C2)CC1 FBMYMDJCGVVKFC-UHFFFAOYSA-N 0.000 description 1
- GYIVRGKZUYEAJA-UHFFFAOYSA-N 6-[4-(2-chloroethoxy)phenyl]imidazo[2,1-b][1,3]thiazole Chemical compound C1=CC(OCCCl)=CC=C1C1=CN(C=CS2)C2=N1 GYIVRGKZUYEAJA-UHFFFAOYSA-N 0.000 description 1
- RWJISOGZLLCXBJ-UHFFFAOYSA-N 6-[4-(3-chloropropoxy)phenyl]imidazo[2,1-b][1,3]thiazole Chemical compound C1=CC(OCCCCl)=CC=C1C1=CN(C=CS2)C2=N1 RWJISOGZLLCXBJ-UHFFFAOYSA-N 0.000 description 1
- LBBFPIWVUDEHCF-UHFFFAOYSA-N 6-[4-(4-chlorobutoxy)phenyl]imidazo[2,1-b][1,3]thiazole Chemical compound C1=CC(OCCCCCl)=CC=C1C1=CN(C=CS2)C2=N1 LBBFPIWVUDEHCF-UHFFFAOYSA-N 0.000 description 1
- YROJYQGROFXURP-UHFFFAOYSA-N 6-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy]phenyl]imidazo[2,1-b][1,3]thiazole;trihydrochloride Chemical compound Cl.Cl.Cl.COC1=CC=CC=C1N1CCN(CCOC=2C=CC(=CC=2)C=2N=C3SC=CN3C=2)CC1 YROJYQGROFXURP-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- NGVNMWXXSGYABS-UHFFFAOYSA-N CCCOC1=C(N=C2N1C=CC=C2)C3=CC=CC=C3 Chemical group CCCOC1=C(N=C2N1C=CC=C2)C3=CC=CC=C3 NGVNMWXXSGYABS-UHFFFAOYSA-N 0.000 description 1
- CDWCKPKEWCJCGB-UHFFFAOYSA-N CCCOC1=C(N=C2N1C=CC=N2)C3=CC=CC=C3 Chemical group CCCOC1=C(N=C2N1C=CC=N2)C3=CC=CC=C3 CDWCKPKEWCJCGB-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9603001A HUP9603001A3 (en) | 1996-10-30 | 1996-10-30 | Heterocycle compounds comprising nitrogen, process for producing them and pharmaceutical compositions containing the same |
| PCT/HU1997/000069 WO1998018797A1 (en) | 1996-10-30 | 1997-10-22 | 2-methoxyphenylpiperazine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK49499A3 true SK49499A3 (en) | 2000-03-13 |
Family
ID=89994394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK494-99A SK49499A3 (en) | 1996-10-30 | 1997-10-22 | 2-methoxyphenylpiperazine derivatives |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6103724A (no) |
| EP (1) | EP0935599A1 (no) |
| JP (1) | JP2001503048A (no) |
| KR (1) | KR20000052872A (no) |
| CN (1) | CN1235606A (no) |
| AP (1) | AP9901532A0 (no) |
| AR (1) | AR010260A1 (no) |
| AU (1) | AU4962097A (no) |
| BG (1) | BG103370A (no) |
| BR (1) | BR9712588A (no) |
| CA (1) | CA2269814A1 (no) |
| CZ (1) | CZ132099A3 (no) |
| EA (1) | EA199900433A1 (no) |
| EE (1) | EE9900182A (no) |
| HU (1) | HUP9603001A3 (no) |
| IL (1) | IL129418A0 (no) |
| IS (1) | IS5026A (no) |
| NO (1) | NO992059D0 (no) |
| OA (1) | OA11041A (no) |
| PL (1) | PL333076A1 (no) |
| SK (1) | SK49499A3 (no) |
| TR (1) | TR199900946T2 (no) |
| TW (1) | TW406083B (no) |
| WO (1) | WO1998018797A1 (no) |
| ZA (1) | ZA979617B (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383327C (en) * | 1999-09-14 | 2009-11-03 | Aventis Pharmaceuticals Inc. | Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists |
| US7125903B1 (en) | 1999-09-14 | 2006-10-24 | Aventis Pharmaceuticals Inc. | Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists |
| SK3512002A3 (en) * | 1999-09-14 | 2003-03-04 | Aventis Pharma Inc | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists |
| US7091199B1 (en) | 1999-09-14 | 2006-08-15 | Aventis Pharmaceuticals Inc. | Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists |
| US7253165B2 (en) * | 1999-09-14 | 2007-08-07 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists |
| EP1268478B1 (en) | 2000-03-31 | 2007-05-02 | Ortho-McNeil Pharmaceutical, Inc. | Phenyl-substituted imidazopyridines |
| TW200811175A (en) * | 2006-06-21 | 2008-03-01 | Nihon Mediphysics Co Ltd | Novel compound with affinity with amyloid |
| KR20100091965A (ko) * | 2007-10-24 | 2010-08-19 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물 |
| CA2704027A1 (en) * | 2007-10-26 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
| US7985752B2 (en) | 2008-05-29 | 2011-07-26 | Sk Holdings Co., Ltd. | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof |
| US7964605B2 (en) | 2008-05-29 | 2011-06-21 | Sk Holdings Co., Ltd. | Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof |
| CN106187873B (zh) * | 2016-07-25 | 2019-11-05 | 宜春学院 | 一种芳胺基烷基氧类化合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880824A (en) * | 1987-09-21 | 1989-11-14 | Ortho Pharmaceutical Corporation | Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers |
| US5688949A (en) * | 1991-04-22 | 1997-11-18 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo 1,5-A!pyrimidine derivatives and anti-inflammatory agent containing the same |
| US5486517A (en) * | 1994-05-10 | 1996-01-23 | Warner-Lambert Company | Benzimidazoles and imidazopyridines as central nervous system agents |
| US6013654A (en) * | 1997-08-14 | 2000-01-11 | Pharmacia & Upjohn Company | Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases |
-
1996
- 1996-10-30 HU HU9603001A patent/HUP9603001A3/hu unknown
-
1997
- 1997-10-22 CN CN97199313A patent/CN1235606A/zh active Pending
- 1997-10-22 SK SK494-99A patent/SK49499A3/sk unknown
- 1997-10-22 CA CA002269814A patent/CA2269814A1/en not_active Abandoned
- 1997-10-22 KR KR1019990703721A patent/KR20000052872A/ko not_active Application Discontinuation
- 1997-10-22 IL IL12941897A patent/IL129418A0/xx unknown
- 1997-10-22 EE EEP199900182A patent/EE9900182A/xx unknown
- 1997-10-22 US US09/284,313 patent/US6103724A/en not_active Expired - Fee Related
- 1997-10-22 AP APAP/P/1999/001532A patent/AP9901532A0/en unknown
- 1997-10-22 AU AU49620/97A patent/AU4962097A/en not_active Abandoned
- 1997-10-22 EA EA199900433A patent/EA199900433A1/ru unknown
- 1997-10-22 EP EP97912393A patent/EP0935599A1/en not_active Withdrawn
- 1997-10-22 WO PCT/HU1997/000069 patent/WO1998018797A1/en not_active Application Discontinuation
- 1997-10-22 BR BR9712588-1A patent/BR9712588A/pt not_active Application Discontinuation
- 1997-10-22 PL PL97333076A patent/PL333076A1/xx unknown
- 1997-10-22 CZ CZ991320A patent/CZ132099A3/cs unknown
- 1997-10-22 JP JP10520214A patent/JP2001503048A/ja active Pending
- 1997-10-22 TR TR1999/00946T patent/TR199900946T2/xx unknown
- 1997-10-27 ZA ZA9709617A patent/ZA979617B/xx unknown
- 1997-10-31 AR ARP970105061A patent/AR010260A1/es unknown
- 1997-11-17 TW TW086117150A patent/TW406083B/zh active
-
1999
- 1999-04-15 IS IS5026A patent/IS5026A/is unknown
- 1999-04-29 BG BG103370A patent/BG103370A/bg unknown
- 1999-04-29 NO NO992059A patent/NO992059D0/no not_active Application Discontinuation
- 1999-04-30 OA OA9900092A patent/OA11041A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA11041A (en) | 2003-03-07 |
| NO992059L (no) | 1999-04-29 |
| TW406083B (en) | 2000-09-21 |
| JP2001503048A (ja) | 2001-03-06 |
| KR20000052872A (ko) | 2000-08-25 |
| PL333076A1 (en) | 1999-11-08 |
| HU9603001D0 (en) | 1996-12-30 |
| AR010260A1 (es) | 2000-06-07 |
| BR9712588A (pt) | 1999-10-26 |
| TR199900946T2 (xx) | 1999-07-21 |
| HUP9603001A2 (hu) | 1998-07-28 |
| BG103370A (bg) | 2000-05-31 |
| IL129418A0 (en) | 2000-02-17 |
| IS5026A (is) | 1999-04-15 |
| CN1235606A (zh) | 1999-11-17 |
| AP9901532A0 (en) | 1999-06-30 |
| NO992059D0 (no) | 1999-04-29 |
| US6103724A (en) | 2000-08-15 |
| EA199900433A1 (ru) | 1999-10-28 |
| EE9900182A (et) | 1999-12-15 |
| CZ132099A3 (cs) | 1999-08-11 |
| ZA979617B (en) | 1998-05-21 |
| AU4962097A (en) | 1998-05-22 |
| HUP9603001A3 (en) | 1999-07-28 |
| EP0935599A1 (en) | 1999-08-18 |
| CA2269814A1 (en) | 1998-05-07 |
| WO1998018797A1 (en) | 1998-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9045428B2 (en) | Substituted heterocyclic compounds | |
| EP2576540B1 (en) | Heteroaryl compounds and methods of use thereof | |
| EP1067123B1 (en) | Nitrogenous heterocyclic compounds | |
| KR101528946B1 (ko) | 4-피리미딘설파미드 유도체 | |
| WO1993003016A1 (en) | Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists | |
| WO2009006580A1 (en) | Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers | |
| CN102391191B (zh) | 2,4-二氨基喹唑啉的哌嗪二硫代甲酸酯衍生物及其制备方法和抗肿瘤用途 | |
| SK49499A3 (en) | 2-methoxyphenylpiperazine derivatives | |
| IE66187B1 (en) | Trisubstituted triazines and pyrimidines a process for their preparation and pharmaceutical compositions containing them | |
| AU2005243482B9 (en) | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | |
| EP3240783B1 (en) | New benzimidazole derivatives as antihistamine agents | |
| US20090181986A1 (en) | Substituted heterocyclic compounds | |
| FI90077C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-/4-/4-(3-substituerad-2-pyridinyl)-1-piperazinyl/butyl/-1-tia-3-azaspiro/4,4/nonan-2,4-dioner | |
| JPH0747574B2 (ja) | ピリジン誘導体及びそれを有効成分とする向精神剤 | |
| CN106317057A (zh) | 具有咪唑并吡嗪类衍生物,其制备及其在医药上的应用 | |
| US11174255B2 (en) | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | |
| SK51052006A3 (sk) | Pyridínové deriváty alkyloxindolov ako aktívne látky voči 5-HT7 receptoru | |
| CN114853672A (zh) | 作为CDKs抑制剂的他克林衍生物及其应用 | |
| EP0484007A1 (en) | DL-3-[4-[4-(2-pyridyl)-1-piperazinyl]-butyl]-1,8,8-trimethyl-3-azabicyclo[3,2,1]octane-2,4-dione having psychotropic and antiemetic effect | |
| KR20110069148A (ko) | 치환된 3-아릴설포닐-피라졸로［1,5-ａ］피리미딘, 세로토닌 5-ＨＴ6 수용체의 길항제, 물질의 제조방법 및 이의 용도 | |
| MXPA99004015A (en) | 2-methoxyphenylpiperazine derivatives | |
| CN114891003A (zh) | 新型二氢嘧啶类化合物、中间体或盐及其制备方法和用途 | |
| JPH02289551A (ja) | ピリミジン誘導体を有効成分とする脳機能改善剤 |